A Phase 4 interventional study of LABA based treatment: indacaterol and LAMA based treatment: tiotropium in COPD, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in China. Per ClinicalTrials.gov, last updated 2019-09-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. indacaterol · Pulmonary Disease, Chronic Obstructive.
Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 4, and was the 45th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
indacaterol: first FDA approval 2011 (ARCAPTA NEOHALER), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 26 · Phase 4 20
First in 2004; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,229 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 57 interventional studies. Of the 52 that completed or were terminated, 39 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 4th largest by enrollment of the 116 interventional ones that give a count, is one of 10 that started in 2013, is one of 24 in phase 4, and was the 86th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set.
A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LABA: Indacaterol, once a day, 150μg each time
Drug: LABA based treatment: indacaterol
LAMA: Tiotropium Bromide, once a day, 18 μg
Drug: LAMA based treatment: tiotropium
LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
Drug: LABA/ICS based treatment: salmeterol/fluticasone
Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
Drug: LABA/ICS based treatment: budesonide/formoterol
Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
Drug: LABA based treatment: indacaterol · Drug: LAMA based treatment: tiotropium
Salmeterol / fluticasone Or budesonide / formoterol
Drug: LAMA based treatment: tiotropium · Drug: LABA/ICS based treatment: salmeterol/fluticasone · Drug: LABA/ICS based treatment: budesonide/formoterol
Drug: theophylline based treatment
non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"
Drug: Other treatment
LABA based treatment: indacaterol
LAMA based treatment: tiotropium
Drug pages: Salmeterol Xinafoate · Fluticasone
LABA/ICS based treatment: salmeterol/fluticasone
Drug pages: Budesonide · Formoterol
LABA/ICS based treatment: budesonide/formoterol
theophylline based treatment
non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
Time frame: Baseline,3 months
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
Time frame: Baseline,12 months
COPD Exacerbation
Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.
Time frame: Baseline,12 months
Change in Health Status Questionnaire MMRC
The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.
Time frame: Baseline,3,6,9,12 months
Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score
The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.
Time frame: Baseline,3,6,9,12 months
Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.
Time frame: Baseline,3,6,9,12 months
A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.
| Milestone | Indacaterol | Tiotropium Bromide | Salmeterol/Fluticasone | Budesonide/ Formoterol | Indacaterol +Tiotropium | LABA/ICS (Or Budesonide/ Formoterol)+ Tiotropium | Oral Theophylline | Other Treatment |
|---|---|---|---|---|---|---|---|---|
| Started | 32 | 276 | 813 | 283 | 9 | 632 | 154 | 30 |
| Completed | 15 | 180 | 571 | 200 | 6 | 452 | 112 | 21 |
| Not completed | 17 | 96 | 242 | 83 | 3 | 180 | 42 | 9 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 2 | 14 | 1 | 0 | 9 | 4 | 0 |
| Withdrew: Lost to follow-up | 10 | 64 | 165 | 53 | 2 | 99 | 30 | 5 |
| Withdrew: Withdrew informed consent | 7 | 17 | 36 | 9 | 0 | 48 | 4 | 3 |
| Withdrew: Other | 0 | 12 | 25 | 20 | 1 | 24 | 4 | 1 |
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
| Liters | Indacaterol | Tiotropium | LABA/ICS | Indacaterol + Tiotropium | LABA/ICS + Tiotropium | Oral Theophylline |
|---|---|---|---|---|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | -0.042 ± 0.1742 | 0.006 ± 0.2537 | 0.033 ± 0.3790 | 0.022 ± 0.1157 | 0.011 ± 0.2417 | 0.012 ± 0.3405 |
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
| Liters | Indacaterol | Tiotropium Bromide | LABA/ICS | Indacaterol +Tiotropium | LABA/ICS + Tiotropium | Oral Theophylline |
|---|---|---|---|---|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | 0.056 ± 0.2137 | -0.036 ± 0.2395 | 0.056 ± 0.4335 | 0.030 ± 0.0854 | -0.028 ± 0.2258 | 0.046 ± 0.3654 |
Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.
| COPD Exacerbations/year | Indacaterol | Tiotropium Bromide | Salmeterol/Fluticasone | Budesonide/ Formoterol | LABA/ICS | Indacaterol +Tiotropium | LABA/ICS + Tiotropium | Oral Theophylline |
|---|---|---|---|---|---|---|---|---|
| COPD Exacerbation | 1.1 ± 3.53 | 0.5 ± 1.89 | 1.1 ± 7.74 | 0.4 ± 1.89 | 0.9 ± 6.72 | 4.1 ± 5.46 | 0.8 ± 3.47 | 1.0 ± 3.57 |
The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.
| Number of participants | Indacaterol | Tiotropium Bromide | LABA/ICS | Indacaterol +Tiotropium | LABA/ICS + Tiotropium | Oral Theophylline |
|---|---|---|---|---|---|---|
| Baseline scale item 0 | 4 | 40 | 161 | 1 | 63 | 31 |
| Baseline scale item 1 | 11 | 114 | 435 | 4 | 226 | 66 |
| Baseline scale item 2 | 14 | 83 | 327 | 1 | 211 | 34 |
| Baseline scale item 3 | 3 | 36 | 154 | 3 | 110 | 19 |
| Baseline scale item 4 | 0 | 3 | 19 | 0 | 22 | 4 |
| 3 month Scale item 0 | 3 | 24 | 101 | 0 | 54 | 20 |
| 3 month Scale item 1 | 9 | 69 | 364 | 4 | 157 | 52 |
| 3 month Scale item 2 | 7 | 54 | 203 | 3 | 133 | 26 |
| 3 month Scale item 3 | 1 | 18 | 67 | 0 | 58 | 11 |
| 3 month Scale item 4 | 0 | 2 | 6 | 0 | 9 | 1 |
| 6 month Scale item 0 | 2 | 23 | 96 | 0 | 37 | 15 |
| 6 month Scale item 1 | 5 | 57 | 290 | 1 | 149 | 43 |
| 6 month Scale item 2 | 8 | 45 | 138 | 4 | 105 | 20 |
| 6 month Scale item 3 | 1 | 13 | 54 | 1 | 44 | 4 |
| 6 month Scale item 4 | 0 | 3 | 5 | 0 | 11 | 0 |
| 9 month Scale item 0 | 3 | 24 | 116 | 0 | 45 | 20 |
| 9 month Scale item 1 | 5 | 52 | 256 | 1 | 127 | 40 |
| 9 month Scale item 2 | 4 | 30 | 131 | 2 | 99 | 19 |
| 9 month Scale item 3 | 1 | 14 | 42 | 0 | 41 | 5 |
| 9 month Scale item 4 | 0 | 1 | 4 | 0 | 9 | 1 |
| 12 month Scale item 0 | 1 | 24 | 150 | 0 | 47 | 20 |
| 12 month Scale item 1 | 5 | 61 | 275 | 2 | 138 | 52 |
| 12 month Scale item 2 | 2 | 33 | 127 | 1 | 102 | 12 |
| 12 month Scale item 3 | 2 | 10 | 41 | 0 | 32 | 4 |
| 12 month Scale item 4 | 0 | 3 | 9 | 0 | 9 | 1 |
The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.
| Score on a scale | Indacaterol | Tiotropium Bromide | LABA/ICS | Indacaterol +Tiotropium | LABA/ICS + Tiotropium | Oral Theophylline |
|---|---|---|---|---|---|---|
| 3 Month | -1.9 ± 5.12 | -2.1 ± 5.58 | -2.3 ± 5.68 | -1.9 ± 2.67 | -1.8 ± 5.96 | -1.8 ± 4.07 |
| 6 Month | -1.9 ± 5.80 | -2.7 ± 5.78 | -2.7 ± 5.89 | -2.7 ± 5.01 | -2.2 ± 6.46 | -2.5 ± 5.65 |
| 9 Month | -4.4 ± 5.27 | -3.1 ± 6.02 | -3.5 ± 6.66 | -9.0 ± 2.65 | -3.1 ± 6.49 | -3.1 ± 6.27 |
| 12 Month | -5.1 ± 3.98 | -2.6 ± 6.74 | -4.1 ± 7.09 | -7.7 ± 0.58 | -3.7 ± 6.45 | -2.4 ± 7.25 |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.
| Units on a scale | Indacaterol | Tiotropium Bromide | LABA/ICS | Indacaterol +Tiotropium | LABA/ICS + Tiotropium | Oral Theophylline |
|---|---|---|---|---|---|---|
| Baseline | 6.7 ± 2.27 | 6.6 ± 2.66 | 6.7 ± 2.66 | 5.4 ± 2.24 | 6.2 ± 2.60 | 7.1 ± 2.81 |
| 3 Month | 1.4 ± 2.61 | 1.2 ± 2.43 | 1.3 ± 2.59 | 0.4 ± 2.07 | 1.1 ± 2.50 | 0.9 ± 2.57 |
| 6 Month | 0.0 ± 2.45 | 1.0 ± 2.67 | 1.4 ± 2.59 | -0.5 ± 2.26 | 0.9 ± 2.36 | 1.2 ± 2.03 |
| 9 Month | 0.7 ± 1.23 | 0.9 ± 2.48 | 1.6 ± 2.78 | 1.0 ± 1.73 | 0.9 ± 2.32 | 1.4 ± 2.68 |
| 12 Month | 0.3 ± 1.70 | 1.0 ± 2.91 | 1.7 ± 3.09 | 1.0 ± 1.73 | 1.0 ± 2.57 | 1.6 ± 2.44 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Indacaterol | — | 1/32 (3.1%) | 2/32 (6.3%) |
| Tiotropium | — | 9/276 (3.3%) | 1/276 (0.4%) |
| Salemeterol/Fluticasone | — | 22/813 (2.7%) | 14/813 (1.7%) |
| Budesonide/Formoterol | — | 2/283 (0.7%) | 1/283 (0.4%) |
| Indacaterol + Tiotropium | — | 2/9 (22.2%) | 1/9 (11.1%) |
| Salemeterol/Fluticasone(or Budesonide/Formoterol)+Tiotropium | — | 11/632 (1.7%) | 5/632 (0.8%) |
| Oral Theophylline | — | 6/154 (3.9%) | 1/154 (0.6%) |
| Other | — | 1/30 (3.3%) | 1/30 (3.3%) |
| Event | Indacaterol | Tiotropium | Salemeterol/Fluticasone | Budesonide/Formoterol | Indacaterol + Tiotropium | Salemeterol/Fluticasone(or Budesonide/Formoterol)+Tiotropium | Oral Theophylline | Other |
|---|---|---|---|---|---|---|---|---|
| Cardiac disorderCardiac disorders | 0/32 | 0/276 | 0/813 | 0/283 | 1/9 | 0/632 | 0/154 | 0/30 |
| Infectious pneumoniaInfections and infestations | 0/32 | 2/276 | 0/813 | 0/283 | 1/9 | 0/632 | 0/154 | 0/30 |
| HypertensionVascular disorders | 0/32 | 0/276 | 0/813 | 0/283 | 1/9 | 0/632 | 0/154 | 0/30 |
| GoitreEndocrine disorders | 0/32 | 0/276 | 0/813 | 0/283 | 0/9 | 0/632 | 0/154 | 1/30 |
| Inguinal herniaGastrointestinal disorders | 1/32 | 0/276 | 0/813 | 0/283 | 0/9 | 0/632 | 0/154 | 0/30 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/32 | 0/276 | 2/813 | 0/283 | 0/9 | 0/632 | 2/154 | 0/30 |
| Acute left ventricular failureCardiac disorders | 0/32 | 0/276 | 0/813 | 0/283 | 0/9 | 0/632 | 1/154 | 0/30 |
| Coronary artery diseaseCardiac disorders | 0/32 | 0/276 | 0/813 | 0/283 | 0/9 | 0/632 | 1/154 | 0/30 |
| Unstable anginaCardiac disorders | 0/32 | 0/276 | 1/813 | 0/283 | 0/9 | 1/632 | 1/154 | 0/30 |
| GastritisGastrointestinal disorders | 0/32 | 0/276 | 0/813 | 0/283 | 0/9 | 0/632 | 1/154 | 0/30 |
| Event | Indacaterol | Tiotropium | Salemeterol/Fluticasone | Budesonide/Formoterol | Indacaterol + Tiotropium | Salemeterol/Fluticasone(or Budesonide/Formoterol)+Tiotropium | Oral Theophylline | Other |
|---|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 0/32 | 0/276 | 0/813 | 0/283 | 1/9 | 1/632 | 0/154 | 0/30 |
| Upper respiratory tract infectionInfections and infestations | 2/32 | 1/276 | 14/813 | 1/283 | 0/9 | 4/632 | 1/154 | 1/30 |
| Age, Continuous(Years) | Indacaterol | Tiotropium Bromide | Salmeterol/Fluticasone | Budesonide/ Formoterol | Indacaterol +Tiotropium | LABA/ICS (Or Budesonide/ Formoterol)+ Tiotropium | Oral Theophylline | Other Treatment | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.12 ± 9.238 | 68.93 ± 9.145 | 67.00 ± 9.353 | 67.02 ± 9.858 | 69.49 ± 8.873 | 67.74 ± 9.427 | 67.86 ± 9.652 | 66.14 ± 10.205 | 67.50 ± 9.453 |
| Sex: Female, Male(Participants) | Indacaterol | Tiotropium Bromide | Salmeterol/Fluticasone | Budesonide/ Formoterol | Indacaterol +Tiotropium | LABA/ICS (Or Budesonide/ Formoterol)+ Tiotropium | Oral Theophylline | Other Treatment | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 52 | 154 | 49 | 1 | 81 | 35 | 5 | 378 |
| Male | 31 | 224 | 659 | 234 | 8 | 551 | 119 | 25 | 1851 |
Ran from Feb 2013 to primary completion in May 2015, 27 months.
Results were first posted in Sep 2019, 4 years 4 months after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 27 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Indacaterol · Tiotropium · Salmeterol Xinafoate · Fluticasone · Budesonide · Formoterol
Pulmonary Disease, Chronic Obstructive →